MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, and Skyepharma, a French independent CDMO, expert in providing innovative solutions for bioproduction as well as complex drugs development and manufacturing, today announced that a significant development milestone has been reached with the completion of the facility and the transfer of MaaT Pharma’s Production and Development teams to the new site. The companies had entered a partnership in February 2022 to build the largest cGMP1 facility, to date, for full ecosystem microbiome therapies in Europe.
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that it will host an investor webcast on Monday, December 12th, 2022 at 12:00 pm EST / 6:00 pm CET to comment on clinical data scheduled to be presented at the 64th American Society of Hematology (ASH) Annual Meeting and provide a corporate update for shareholders and the broader financial community.
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that Hervé Affagard, CEO and co-founder of MaaT Pharma, and Siân Crouzet, CFO of MaaT Pharma, will participate in three upcoming investor conferences.
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported its cash position as of June 30, 2022, and its revenues for the second quarter of 2022.
